Sequential Treatment by Polidocanol and Radiofrequency Ablation of Large Benign Partially Cystic Thyroid Nodules with Solid Components: Efficacy and Safety

Y. Lin,P. Li,Y-P Shi,X-Y Tang,M. Ding,Y. He,B. Zhai

DOI: https://doi.org/10.1016/j.diii.2019.11.005

IF: 7.242

2020-01-01

Diagnostic and Interventional Imaging

Abstract:Purpose: The purpose of this study was to retrospectively evaluate the efficacy and safety of a sequential treatment including percutaneous polidocanol sclerotherapy and radiofrequency ablation (RFA) in terms of volume reduction and complication rate in large, benign, partially cystic thyroid nodules with solid components. Materials and method: From April 2017 to April 2019, 46 patients with 47 large benign partially cystic thyroid nodules underwent sequential treatment. There were 14 men and 32 women with a mean age of 49.9 +/- 11.5 (SD) years (range: 18-75 years). The volume of initial nodules was 12.7 +/- 12.3 (SD) mL (range: 2.16-75.62 mL). Volume reduction after percutaneous polidocanol sclerotherapy and further RFA was evaluated respectively. Patients had clinical and ultrasound evaluations at a follow-up time of 12.1 +/- 5.3 (SD) months (range: 1.5-23.9 months). Technical success and complications were accessed retrospectively. Results: After unsatisfying results with polidocanol sclerotherapy alone the 46 patients with 47 large benign partially cystic thyroid nodules had further RFA. Mean volume reduction of 47 nodules was 90.5 +/- 11.3 (SD) % (range: 43.9-99.3%) one month after RFA, 94.9 +/- 6.2 (SD) % (range: 66.9-99.5%) three months after RFA, and 95.8 +/- 5.5 (SD) % (range: 71.0-99.8%) six months after RFA. No recurrence or nodule enlargement after RFA was observed at the last follow-up. The complication rate of RFA was 12.5% (8/46 patients), with minor complications only. Conclusions: The sequential treatment regimen, including percutaneous polidocanol sclerotherapy and RFA, is an appropriate and safe treatment strategy for large benign partially cystic thyroid nodules with solid components. (C) 2019 Published by Elsevier Masson SAS on behalf of Societe francaise de radiologie.